Синдром Жильбера как модель изучения эффектов билирубина

Многочисленные научные исследования, проводимые в течение последних лет, расширяют наши представления о физиологических и патофизиологических эффектах билирубина. В настоящем обзоре литературы авторы на примере синдрома Жильбера, как классического состояния, протекающего с гипербилирубинемией, обсуждают результаты клинических и экспериментальных исследований, демонстрирующих протективные механизмы и защитную роль повышенной концентрации билирубина в отношении заболеваний, сопровождающихся метаболическим воспалением, онкологических заболеваний и ряда других. Авторы делают акцент на обсуждаемой в последних научных работах гормональной функции билирубина и его потенциального терапевтического эффекта. Цель настоящего обзора литературы заключается в расширении представлений о билирубине с привычных для клинициста в контексте конечного продукта метаболизма гема и антиоксиданта до сигнальной молекулы, участвующей в патофизиологии многих заболеваний.

синдром Жильбера, желтуха, гипербилирубинемия, гипобилирубинемия, УДФ-ГТ1-A1, PPARα, метаболические заболевания

1. Dhawan A., Lawlor M. W., Mazariegos G. V., et al. Disease burden of Crigler-Najjar syndrome: Systematic review and future perspectives. J Gastroenterol Hepatol. 2019 Oct 24; 35 (4): 530-543. doi: 10.1111/jgh.14853.

2. Roy-Chowdhury, N.; Wang, X.; Roy-Chowdhury, J. Bile pigment metabolism and its disorders. In Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal Disorders; Pyeritz, R., Korf, B., Grody, W., Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 507-553.

3. Wagner K.H., Shiels R. G., Lang C. A., et al. Diagnostic criteria and contributors to Gilbert’s syndrome. Crit Rev Clin Lab Sci. 2018. Mar; 55(2): 129-139. doi: 10.1080/10408363.2018.1428526.

4. Hamoud A.R., Weaver L., Stec D. E., et al. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol Metab. 2018 Mar; 29(3): 140-150. doi: 10.1016/j.tem.2018.01.002.

5. Adeosun S.O., Moore K. H., Lang D. M., et al. A novel fluorescence-based assay for the measurement of biliverdin reductase activity. React Oxyg Species (Apex). 2018 Jan1; 5 (13): 35-45. doi: 10.20455/ros.2018.809.

6. Gordon D.M., Blomquist T. M., Miruzzi S. A., et al. RNA sequencing in human HepG2 hepatocytes reveals PPAR-α mediates transcriptome responsiveness of bilirubin. Physiol Genomics. 2019 Jun 1;51(6):234-240. doi: 10.1152/physiolgenomics.00028.2019.

7. Weaver L., Hamoud A. R., Stec D. E., et al. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018 Jun 1;314(6): G668-G676. doi: 10.1152/ajpgi.00026.2018.

8. Steventon G. Uridine diphosphate glucuronosyltransferase 1A1. Xenobiotica. 2020 Jan;50(1):64-76. doi: 10.1080/00498254.2019.1617910.

9. Wang J., Yin J., Xue M., et al. Roles of UGT1A1 Gly71Arg and TATA promoter polymorphisms in neonatal hyperbilirubinemia: A meta-analysis. Gene. 2020 Apr; 30;736:144409. doi: 10.1016/j.gene.2020.144409.

10. Chiddarwar A.S., D’Silva S.Z., Colah R. B., et al. Genetic variations in bilirubin metabolism genes and their association with unconjugated hyperbilirubinemia in adults. Ann Hum Genet. 2017 Jan;81(1):11-19. doi: 10.1111/ahg.12179.

11. Chen H., Zhong D., Gao Z., et al. Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin. Open Life Sci. 2022 Mar 18;17(1):221-229. doi: 10.1515/biol-2022-0021.

12. Gu L., Han Y., Zhang D., et al. Genetic testing of UGT1A1 in the diagnosis of Gilbert syndrome: The discovery of seven novel variants in the Chinese population. Mol Genet Genomic Med. 2022 Jul;10(7): e1958. doi: 10.1002/mgg3.1958.

13. Nguyen T.T., Zhao W., Yang X., et al. The relationship between hyperbilirubinemia and the promoter region and first exon of UGT1A1 gene polymorphisms in Vietnamese newborns. Pediatr Res. 2020 Dec;88(6):940-944.doi: 10.1038/s41390-020-0825-6.

14. Maruo Y., Nakahara S., Yanagi T., et al. Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol. 2016 Feb;31(2):403-8. doi: 10.1111/jgh.13071.

15. Sanchez-Dominguez C. N., Gallardo-Blanco H. L., Salinas-Santander M.A., et al. Uridine 5′-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease. Experimental and Therapeutic Medicine. 2018 Jul;16(1):3-11. doi: 10.3892/etm.2018.6184.

16. Tátrai P., Krajcsi P. Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing. Pharmaceutics. 2020 Aug 11;12(8):755. doi: 10.3390/pharmaceutics12080755.

17. Karas S., Innocenti F. All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO Oncol Pract. 2022 Apr;18(4):270-277. doi: 10.1200/OP.21.00624.

18. Owens D., Evans J. Population studies on Gilbert’s syndrome. J Med Genet. 1975 Jun;12(2):152-6. doi: 10.1136/jmg.12.2.152.

19. Méndez L., Lagoa M., Quiroga T., et al. Prevalencia de síndrome de Gilbert y sus determinantes genéticas en población chilena [Prevalence of Gilbert syndrome and its genetic determinants in Chile]. Rev Med Chil. 2013 Oct;141(10):1266-74. doi: 10.4067/S0034-98872013001000005.

20. Gwee K.A., Koay E. S., Kang J. Y. The prevalence of isolated unconjugated hyperbilirubinaemia (Gilbert’s syndrome) in subjects attending a health screening programme in Singapore. Singapore Med J. 1992 Dec;33(6):588-9.

21. Sieg A., Arab L., Schlierf G., et al. Die Prävalenz des Gilbert-Syndroms in Deutschland [Prevalence of Gilbert’s syndrome in Germany]. Dtsch Med Wochenschr. 1987 Jul 31;112(31-32):1206-8. doi: 10.1055/s-2008-1068222.

22. Bakhotmah M.A., Gasem A. A., Bairotee B. Asymptomatic unconjugated hyperbilirubinemia (Gilbert syndrome) among Saudis in Jeddah. Ann Saudi Med. 1995 Jul;15(4):422-3. doi: 10.5144/0256-4947.1995.422.

23. Koul P.A., Geelani S. A., Mudasir S. Benign jaundice in healthy blood donors in the Kashmir valley of indian subcontinent.Int J Intern Med. 2006;6:1-5.

24. Hemmati F., Saki F., Saki N., et al. Gilbert syndrome in Iran, Fars Province. Ann Saudi Med. 2010; Jan-Feb;30(1):84. doi: 10.4103/0256-4947.59376.

25. Horsfall L.J., Zeitlyn D., Tarekegn A., et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011; Mar;75(2):236-46. doi: 10.1111/j.1469-1809.2010.00638.x.

26. Botvinyev O. K., Dubrovina G. M., Kolotilina A. I. Defeat of the gastrointestinal tract in children with Gilbert’s syndrome.Russian Bulletin of perinatology and Pediatrics. 2015; 60 (3): 104-107. (in Russ.)@@ Ботвиньев, О. К. Поражение отделов желудочно-кишечного тракта у детей с синдромом Жильбера / О. К. Ботвиньев, Г. М. Дубровина, А. И. Колотилина // Российский вестник перинатологии и педиатрии. - 2015. - Т. 60. - № 3. - С. 104-107.

27. Dubrovina, G. M., Kolotilina A. I., Botvinyev O. K. Features of esophageal lesion in children with Gilbert’s syndrome. Clinical prospects of gastroenterology, hepatology. 2015; 6:52-55. (in Russ.)@@ Дубровина, Г. М. Особенности поражения пищевода у детей с синдромом Жильбера / Г. М. Дубровина, А. И. Колотилина, О. К. Ботвиньев // Клинические перспективы гастроэнтерологии, гепатологии. - 2015. - № 6. - С. 52-55.

28. Bale G., Avanthi U. S., Padaki N. R., et al. Incidence and Risk of Gallstone Disease in Gilbert’s Syndrome Patients in Indian Population. J Clin Exp Hepatol. 2018 Dec;8(4):362-366. doi: 10.1016/j.jceh.2017.12.006.

29. Khodzhieva G. S. Frequency of spread and features of the course of functional diseases of the biliary tract in Gilbert’s syndrome. New science: Strategies and vectors of development. 2017;2(3):12-15. (in Russ.)@@ Ходжиева, Г. С. Частота распространения и особенности течения функциональных заболеваний билиарного тракта при синдроме Жильбера / Г. С. Ходжиева // Новая наука: Стратегии и векторы развития. - 2017. - Т. 2. - № 3. - С. 12-15.

30. Gubergrits N. B., Lukashevich G. M., Borodiy K. N. Gilbert’s syndrome and pancreatitis: modern ideas about pathogenesis, diagnosis and treatment. Bulletin of the club of pancreatologists. 2021;3(52): 11-18. doi: 10.33149/vkp.2021.03.02.@@ Губергриц, Н. Б. Синдром Жильбера и панкреатит: современные представления о патогенезе, диагностике и лечении / Н. Б. Губергриц, Г. М. Лукашевич, К. Н. Бородий // Вестник клуба панкреатологов. - 2021. - № 3(52). - С. 11-18. - doi: 10.33149/vkp.2021.03.02.

31. Vítek L., Tiribelli C. B.Intestinal Integrity, the Microbiome, and Inflammation. N Engl J Med. 2020 Aug 13;383(7):684-686. doi: 10.1056/NEJMcibr2013250.

32. Hinds T. D. Jr., Creeden J. F., Gordon D. M., et al. Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma β-hydroxybutyrate. Front Pharmacol. 2020 Dec 18;11:594574. doi: 10.3389/fphar.2020.594574.

33. Stec D.E., Gordon D. M., Nestor-Kalinoski A.L., et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020 Mar 2;10(3):387. doi: 10.3390/biom10030387.

34. Kim J.Y., Lee D. Y., Kang S., et al. Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury. Biomaterials. 2017 Jul;133:1-10. doi: 10.1016/j.biomaterials.2017.04.011.

35. Kim D.E., Lee Y., Kim M., et al. Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma. Biomaterials. 2017 Sep;140:37-44. doi: 10.1016/j.biomaterials.2017.06.014.

36. Lee Y., Sugihara K., Gillilland M. G., et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2020 Jan;19(1):118-126. doi: 10.1038/s41563-019-0462-9.

37. Hinds T. D. Jr., Stec D. E. Bilirubin safeguards cardiorenal and metabolic diseases: a protective role in health. Curr Hypertens Rep. 2019 Oct 10;21(11):87. doi: 10.1007/s11906-019-0994-z.

38. Vítek L. Bilirubin as a predictor of diseases of civilization. Is it time to establish decision limits for serum bilirubin concentrations? Arch Biochem Biophys. 2019 Sep 15;672:108062. doi: 10.1016/j.abb.2019.108062.

39. Xiang G.Q., Sun F. R., Wang B. Y. Gilbert’s syndrome: hyperbilirubinemia enemy or friend. Zhonghua Gan Zang Bing Za Zhi. 2021; Oct 20;29(10):1024-1027. doi: 10.3760/cma.j.cn501113-20200212-00041.

40. Pereira E.E.B., Leitão L. P.C., Andrade R. B., et al. UGT1A1 Gene Polymorphism Contributes as a Risk Factor for Lung Cancer: A Pilot Study with Patients from the Amazon. Genes (Basel). 2022 Mar 11;13(3):493. doi: 10.3390/genes13030493.

41. Horsfall L.J., Burgess S., Hall I. Genetically raised serum bilirubin levels and lung cancer: a cohort study and Mendelian randomisation using UK Biobank. Thorax. 2020 Nov;75(11):955-964. doi: 10.1136/thoraxjnl-2020-214756.

42. Seyed Khoei N., Jenab M., Murphy N., et al. Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC Med 2020 Sep 3;18(1): 229. doi: 10.1186/s12916-020-01703-w.

43. Creeden J.F., Gordon D. M., Stec D. E., et al. Bilirubin as a metabolic hormone: The physiological relevance of low levels. Am J Physiol Endocrinol Metab. 2021 Feb 1;320(2): E191-E207. doi: 10.1152/ajpendo.00405.2020.

44. Kwon Y.J., Lee Y. J., Park B. J., et al. Total serum bilirubin and 8-year incident type 2 diabetes mellitus: The Korean Genome and Epidemiology Study. Diabetes Metab. 2018 Sep;44(4):346-353. doi: 10.1016/j.diabet.2017.07.004.

45. Yang M., Ni C., Chang B., et al. Association between serum total bilirubin levels and the risk of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019 Jun;152: 23-28. doi: 10.1016/j.diabres.2019.04.033.

46. Uribe-Weichers A.C., Gómez-Pérez F.J., Lam-Chung C.E., et al. Patients with Gilbert syndrome and type 2 diabetes have lower prevalence of microvascular complications. Metabol Open. 2021 Jul 28;11: 100114. doi: 10.1016/j.metop.2021.100114.

47. Hana C.A., Tran L. V., Mölzer C., et al. Serum metabolomics analysis reveals increased lipid catabolism in mildly hyperbilirubinemic Gilbert’s syndrome individuals. Metabolism. 2021 Dec;125: 154913. doi: 10.1016/j.metabol.2021.154913.

48. Zengin O., Sahiner E. S., Inan O., et al. Endothelial Dysfunction and Endocan Levels in Patients with Gilbert Syndrome and Moderate Hyperbilirubinemia. Angiology. 2022 Nov-Dec;73(10):920-926. doi: 10.1177/00033197211057692.

49. Abdurakhmanov Z.M., Umarov B. Ya., Abdurakhmanov M. M. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-618. (in Russ.) doi: 10.20996/1819-6446-2021-08-08.@@ Абдурахманов З. М., Умаров Б. Я., Абдурахманов М. М. Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Рациональная Фармакотерапия в Кардиологии. 2021;17(4):612-618. doi: 10.20996/1819-6446-2021-08-08.

50. Kundur A.R., Santhakumar A. B., Bulmer A. C., et al. Mildly elevated unconjugated bilirubin is associated with reduced platelet activation-related thrombogenesis and inflammation in Gilbert’s syndrome. Platelets. 2017 Dec;28(8):779-785. doi: 10.1080/09537104.2017.1280146.

51. Cure М. C., Cure E., Kirbas A., et al. The effects of Gilbert’s syndrome on the mean platelet volume and other hematological parameters. Blood Coagul Fibrinolysis. 2013 Jul;24(5):484-8. doi: 10.1097/MBC.0b013e32835e4230.

52. Hinds T. D. Jr., Stec D. E. Bilirubin, a cardiometabolic signaling molecule. Hypertension. 2018 Oct;72(4):788-795. doi: 10.1161/HYPERTENSIONAHA.118.11130.

53. Gordon D. M., Neifer K. L., Hamoud A. A., et al. Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor α. J Biol Chem 2020 Jul 17;295(29): 9804-9822. doi: 10.1074/jbc.RA120.013700.

54. Meixiong J., Vasavda C., Green D., et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch. Elife. 2019 Jan 21;8: e44116. doi: 10.7554/eLife.44116.

55. Takei R., Inoue T., Sonoda N., et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One. 2019 Oct 2;14(10): e0223302. doi: 10.1371/journal.pone.0223302.

56. Kundur A. R., Singh I., Bulmer A. C. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert’s syndrome? Atherosclerosis. 2015 Mar;239(1):73-84. doi: 10.1016/j.atherosclerosis.2014.12.042.

57. Higuchi S., Kabeya Y., Uchida J., et al. Low bilirubin levels indicate a high Risk of cerebral deep white matter lesions in apparently healthy subjects. Sci Rep. 2018 Apr 24;8(1):6473. doi: 10.1038/s41598-018-24917-8.

58. Buyukasik Y., Akman U., Buyukasik N. S., et al. Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilbert’s syndrome. Am J Med Sci. 2008 Feb;335(2):115-9. doi: 10.1097/MAJ.0b013e318142be0d.

59. Sarlak H., Arslan E., Cakar M., et al. Relation between unconjugated bilirubin and RDW, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio in Gilbert’s syndrome. Springerplus. 2016 Aug 22;5(1):1392. doi: 10.1186/s40064-016-3085-5.

60. Méndez-Sánchez N., González V., Flores A., et al. Delayed gastric emptying in subjects with Gilbert’s syndrome. Hepatogastroenterology. 2001 Jul-Aug;48(40):1183-5.

61. Radlović N., Leković Z., Mladenović M., et al. Gilbert’s syndrome in children-our experience. Srp Arh Celok Lek. 2007 May-Jun;135(5-6):317-20. doi: 10.2298/sarh0706317r.

62. Deetman P. E., Bakker S. J., Kwakernaak A. J., et al. PREVEND Study Group. The relationship of the anti-oxidant bilirubin with free thyroxine is modified by insulin resistance in euthyroid subjects. PLoS One. 2014 Mar 3;9(3): e90886. doi: 10.1371/journal.pone.0090886.

63. Cuperus F. J., Iemhoff A. A., van der Wulp M., et al. Acceleration of the gastrointestinal transit by polyethylene glycol effectively treats unconjugated hyperbilirubinaemia in Gunn rats. Gut. 2010 Mar;59(3):373-80. doi: 10.1136/gut.2009.183921.

64. Nishioka T., Hafkamp A. M., Havinga R., et al. Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr. 2003 Sep;143(3):327-34. doi: 10.1067/s0022-3476(03)00298-1.

65. Landerer S., Kalthoff S., Paulusch S. et al. A Gilbert syndrome-associated haplotype protects against fatty liver disease in humanized transgenic mice. Sci Rep. 2020 May 26;10(1):8689. doi: 10.1038/s41598-020-65481-4.

66. Stec D.E, Tiribelli C., Badmus O. O., et al. Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases. Kidney360. 2022 Mar 25;3(5):945-953. doi: 10.34067/KID.0000062022.

67. Thomas D. T., DelCimmuto N.R., Flack K. D., et al. Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin. Antioxidants (Basel). 2022 Jan 18;11(2):179. doi: 10.3390/antiox11020179.